Merrimack Pharmaceuticals Inc
Performance History
| Key Stats | |
|---|---|
| Open | $12.75 |
| Prev. Close | $12.78 |
| EPS | -0.10 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 3, 2023 |
| Dividend Yield % | 57.71% |
| Market Cap | $182.16M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 12.68 | 12.85 |
| 52 Week Range | 10.10 | 13.15 |
| Ratios | |
|---|---|
| P/B Ratio | 9.82 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$1.43M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -8.96% |
| EPS | -0.10 |
Score Breakdown
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| MACK | Market | |
|---|---|---|
| Value | 41 | 42 |
| Quality | 42 | 46 |
| Ownership | 25 | 39 |
| Growth | 99 | 44 |
| Dividends | 33 | 32 |
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Gary L. Crocker M.B.A., MBA
- Headquarters
- Cambridge
- Employees
- 0
Keep an eye on Merrimack Pharmaceuticals Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.